search
Back to results

Validation of the GenePOC GBS Assay for the Detection of the Cfb Gene From Streptococcus Agalactiae Strains

Primary Purpose

Streptococcus Agalactiae Infection

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Comparison between GenePOC PCR and Reference Method
Sponsored by
Meridian Bioscience, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Streptococcus Agalactiae Infection focused on measuring Polymerase Chain Reaction (PCR), GBS, Streptococcus agalactiae, Antepartum women

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Antepartum pregnant women
  • 18 years old and more
  • Being at a gestation period of 35 to 37 weeks.
  • Vaginal/rectal swab specimen
  • Transport and storage times, and conditions (e.g. room temperature and/or refrigerated) within the labeled indications.

    • Fresh specimens available to be tested with the GenePOC GBS System within 96 hours (4 days) of collection if kept at 2-25°C
    • Fresh specimens must be tested with the Reference Method within 96 hours (4 days) of collection if kept at 2-25°C
  • The GenePOC GBS System and the Reference Method will be performed according to the GenePOC GBS Investigation Documents.
  • Materials use within their expiration date

Exclusion Criteria:

  • Non pregnant women
  • Less than 18 years old
  • Gestation not between 35-37 weeks
  • Transport and storage times and conditions that exceed these Study Protocol requirements
  • The GenePOC GBS System and the Reference Method not performed according to the GenePOC GBS Investigation Documents
  • Materials used beyond their expiration date
  • Specimens without all test results required by this Study Protocol. Specimens that are inadvertently entered into the study that do not meet the specimen inclusion criteria will be made non-compliant.
  • The GenePOC GBS System and the Reference Method not performed according to the GenePOC GBS Investigation Documents.

Sites / Locations

  • Detroit Medical Center University Laboratories
  • Tricore Laboratory University of New Mexico
  • Mount Sinai Hospital Joseph and Wolf Lebovic Health Complex
  • CHU de Québec - Université Laval

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Accuracy Testing

Arm Description

Comparison between GenePOC PCR and Reference Method

Outcomes

Primary Outcome Measures

Performance Characteristics
To establish the performance characteristics of the GenePOC GBS System for its use in determining the presence of GBS in vaginal/rectal swab, after Lim Broth enrichment, specimens from antepartum pregnant women. Sensitivity and specificity will be established in comparison to the Reference Method. Sensitivity performance results from the comparison of specimens being reported as positive by both method against the total number of specimen reported as positive on the Reference Method only. Sensitivity is reported as a percentage (i.e. concondant positives / concordant positive + discordant positive ([False Negative]). Specificity performance results from the comparison of specimens being reported as negative by both method against the total number of specimen reported as negative on the Reference Method only. Specificity is reported as a percentage (i.e. concondant negatives / concordant negatives + discordant negatives ([False Positive]).

Secondary Outcome Measures

Positive and Negative Predictive Values
To estimate the Positive and Negative Predictive Values (PPV and NPV) of the GenePOC GBS System. PPV results from the comparison of specimens being reported as positive by both method against the total number of specimen reported as positive on the Investigational test only. PPV is reported as a percentage (i.e. concondant positives / concordant positive + discordant positive ([False Positive]). NPV results from the comparison of specimens being reported as negative by both method against the total number of specimen reported as negative on the Investigational test only. NPV is reported as a percentage (i.e. concondant negatives / concordant negatives + discordant negatives ([False Negative]).
Unresolved Sample Results
To estimate the rate of unresolved results for the GenePOC GBS System due to Sample Processing control failure (unresolved sample results).
Indeterminate Sample Results
To estimate the rate of indeterminate results for the GenePOC GBS Test due to an Instrument failure (indeterminate sample results).

Full Information

First Posted
March 15, 2016
Last Updated
April 29, 2021
Sponsor
Meridian Bioscience, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT02718157
Brief Title
Validation of the GenePOC GBS Assay for the Detection of the Cfb Gene From Streptococcus Agalactiae Strains
Official Title
Prospective Study for Clinical Validation of the Molecular-Based GenePOC GBS Assay for the Detection of the Cfb Gene From Streptococcus Agalactiae Strains in Vaginal/Rectal Swab Specimens, After Lim Broth Enrichment, From Pregnant Women
Study Type
Interventional

2. Study Status

Record Verification Date
November 2018
Overall Recruitment Status
Completed
Study Start Date
August 10, 2016 (Actual)
Primary Completion Date
February 7, 2017 (Actual)
Study Completion Date
February 7, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Meridian Bioscience, Inc.

4. Oversight

Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
The primary purpose of this clinical investigation is to verify the performance of the GenePOC GBS Assay on the GenePOC Instrument. This will be achieved by comparing the Assay to the a Culture, a conventional method for detection of Streptococcus agalactiae in vaginal/rectal swab specimens from antepartum women.
Detailed Description
The GenePOC GBS Test performed on the GenePOC System is a qualitative in vitro diagnostic (IVD) test designed to detect Group B Streptococcus (GBS) DNA from vaginal/rectal swabs from antepartum women following enrichment in Lim broth for 18-24 hours. The GenePOC GBS Test utilizes automated sample preparation and real-time polymerase chain reaction (PCR) to detect a cfb gene sequence specific to the Streptococcus agalactiae genome. The GenePOC GBS Test is indicated for the identification of antepartum GBS colonization and does not provide susceptibility results. Culture isolates are needed for performing susceptibility testing as recommended for penicillin-allergic women. The GenePOC GBS is an IVD system is comprised of the GenePOC Diagnostics System and the GenePOC Group B Step [GBS] Test, the components of which are: Instrument GBS disposable microfluidic cartridges (PIE) (described in this document as PIEs because of the shape of the cartridge) GBS Sample Buffer Tube (SBT) Sample Transfer Device (STD). The GenePOC Instrument is fully automated and integrates sample lysis, dilution, amplification and detection of the target sequence in complex samples using real-time Polymerase chain reaction (rtPCR). User intervention is only required for discharging the patient sample into the SBT (sample Buffer Tube), transferring the sample into the PIE and for loading/unloading the PIEs into the instrument. The GenePOC instrument consists of a rotor to spin the PIEs, temperature control, fluorescence detection, a tactile user-friendly interface, two barcode readers, and integrated firmware and software to deliver results to the user. The PIE is a closed system that prevents the risk of contamination. Lim Broth is used for the selective enrichment of group B streptococci (Streptococcus agalactiae). An aliquot of the broth is mixed with GenePOC Sample Buffer Tube Reagent (SBT), after which a sample is transferred to the GenePOC GBS PIE. The GenePOC GBS PIE is then automatically processed by the GenePOC Instrument. On completion of a run, the user removes the processed PIEs from the instrument and discards them according to local biological waste management procedures. One GenePOC instrument per site will be allocated. The purpose of the clinical investigation is to enroll sufficient specimens from four (4) Clinical Centers to obtain a total of 150 specimens positive for GBS based on the Reference Method final result. Subject Informed consent is not required for this clinical trial as the testing will be performed on excess de-identified specimens only.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Streptococcus Agalactiae Infection
Keywords
Polymerase Chain Reaction (PCR), GBS, Streptococcus agalactiae, Antepartum women

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
771 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Accuracy Testing
Arm Type
Experimental
Arm Description
Comparison between GenePOC PCR and Reference Method
Intervention Type
Device
Intervention Name(s)
Comparison between GenePOC PCR and Reference Method
Intervention Description
Antepartum women swab specimen incubated in Lim Broth will be tested with the GenePOC GBS test on the GenePOC Instrument. The results will be compared to Reference Method defined as incubated Lim broth subcultured onto blood agar plate for observation of a Streptococcus agalactiae strain.
Primary Outcome Measure Information:
Title
Performance Characteristics
Description
To establish the performance characteristics of the GenePOC GBS System for its use in determining the presence of GBS in vaginal/rectal swab, after Lim Broth enrichment, specimens from antepartum pregnant women. Sensitivity and specificity will be established in comparison to the Reference Method. Sensitivity performance results from the comparison of specimens being reported as positive by both method against the total number of specimen reported as positive on the Reference Method only. Sensitivity is reported as a percentage (i.e. concondant positives / concordant positive + discordant positive ([False Negative]). Specificity performance results from the comparison of specimens being reported as negative by both method against the total number of specimen reported as negative on the Reference Method only. Specificity is reported as a percentage (i.e. concondant negatives / concordant negatives + discordant negatives ([False Positive]).
Time Frame
At the time of the results with Reference Method is confirmed, up to 6 months
Secondary Outcome Measure Information:
Title
Positive and Negative Predictive Values
Description
To estimate the Positive and Negative Predictive Values (PPV and NPV) of the GenePOC GBS System. PPV results from the comparison of specimens being reported as positive by both method against the total number of specimen reported as positive on the Investigational test only. PPV is reported as a percentage (i.e. concondant positives / concordant positive + discordant positive ([False Positive]). NPV results from the comparison of specimens being reported as negative by both method against the total number of specimen reported as negative on the Investigational test only. NPV is reported as a percentage (i.e. concondant negatives / concordant negatives + discordant negatives ([False Negative]).
Time Frame
At the time of the results with Reference Method is confirmed, up to 6 months
Title
Unresolved Sample Results
Description
To estimate the rate of unresolved results for the GenePOC GBS System due to Sample Processing control failure (unresolved sample results).
Time Frame
At the time of the results with Reference Method is confirmed, up to 6 months
Title
Indeterminate Sample Results
Description
To estimate the rate of indeterminate results for the GenePOC GBS Test due to an Instrument failure (indeterminate sample results).
Time Frame
At the time of the results with Reference Method is confirmed, up to 6 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Antepartum pregnant women 18 years old and more Being at a gestation period of 35 to 37 weeks. Vaginal/rectal swab specimen Transport and storage times, and conditions (e.g. room temperature and/or refrigerated) within the labeled indications. Fresh specimens available to be tested with the GenePOC GBS System within 96 hours (4 days) of collection if kept at 2-25°C Fresh specimens must be tested with the Reference Method within 96 hours (4 days) of collection if kept at 2-25°C The GenePOC GBS System and the Reference Method will be performed according to the GenePOC GBS Investigation Documents. Materials use within their expiration date Exclusion Criteria: Non pregnant women Less than 18 years old Gestation not between 35-37 weeks Transport and storage times and conditions that exceed these Study Protocol requirements The GenePOC GBS System and the Reference Method not performed according to the GenePOC GBS Investigation Documents Materials used beyond their expiration date Specimens without all test results required by this Study Protocol. Specimens that are inadvertently entered into the study that do not meet the specimen inclusion criteria will be made non-compliant. The GenePOC GBS System and the Reference Method not performed according to the GenePOC GBS Investigation Documents.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Patrice Allibert
Organizational Affiliation
Meridian Bioscience, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Detroit Medical Center University Laboratories
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48201
Country
United States
Facility Name
Tricore Laboratory University of New Mexico
City
Albuquerque
State/Province
New Mexico
ZIP/Postal Code
87102
Country
United States
Facility Name
Mount Sinai Hospital Joseph and Wolf Lebovic Health Complex
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 1X5
Country
Canada
Facility Name
CHU de Québec - Université Laval
City
Québec
ZIP/Postal Code
G1V 4G2
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Validation of the GenePOC GBS Assay for the Detection of the Cfb Gene From Streptococcus Agalactiae Strains

We'll reach out to this number within 24 hrs